eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

Thornton & Ross Ltd

Telephone: +44 (0)1484 842217
Fax: +44 (0)1484 847301
WWW: http://www.thorntonandross.com
Medical Information Direct Line: +44(0)1484 848 251
Medical Information e-mail: phv@thorntonross.co.uk
Customer Care direct line: +44(0)1484 842 217
Medical Information Fax: +44(0)1484 847 301

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 24/11/2011
SPC Pripsen Mebendazole Tablets 100 mg


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Pripsen Mebendazole Tablets 100 mg

Mebendazole Tablets 100 mg

Boots Family Threadworm Tablets


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Mebendazole 100.00 mg USP

For excipients, see 6.1


Go to top of the page
3. PHARMACEUTICAL FORM

Chewable Tablets

A mottled off-white, round, flat faced tablet with a bevelled edge.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

For the treatment of threadworm (enterobiasis) infestation.


Go to top of the page
4.2 Posology and method of administration

Route of Administration: Oral

Adults, the elderly and children over two years old:

One tablet to be chewed or swallowed whole. The efficacy in threadworm infestations is such that treatment failure will be rare. However, the possibility of re-infection means that some patients may require a second tablet after two weeks, if re-infected.

It is strongly recommended that all members of the family are treated at the same time.

Not recommended for children under two years of age.


Go to top of the page
4.3 Contraindications

Hypersensitivity to any of the ingredients.

Not to be taken during pregnancy or whilst breast feeding.

Mebendazole has not been studied extensively in children under two years of age – for this reason it is not currently recommended for children under two years of age.


Go to top of the page
4.4 Special warnings and precautions for use

1) If, after two weeks, you need to take the second tablet, following which your symptoms persist, then consult your doctor.

2) Patients with rare hereditary problems of fructose intolerance should not take this medicine as it contains sorbitol.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None known


Go to top of the page
4.6 Pregnancy and lactation

Mebendazole has shown embryotoxic and teratogenic activity in rats at single oral doses. No such findings have been reported in the rabbit, dog, sheep or horse. Since there is a risk that Mebendazole could produce foetal damage if taken during pregnancy, it is contraindicated in pregnant women. No information on secretion into breast milk is available so mothers taking the drug should not breast feed.


Go to top of the page
4.7 Effects on ability to drive and use machines

None known


Go to top of the page
4.8 Undesirable effects

Side effects reported have been minor. Hypersensitivity reactions including exanthema, rash, urticaria and angioedema have been reported rarely. Transient abdominal pain and diarrhoea have been reported only rarely in cases of massive infestation and expulsion of worms. (Slight headache and dizziness have occasionally been reported).


Go to top of the page
4.9 Overdose

Raised liver enzyme values, alopecia and bone marrow depression have been reported following high dose mebendazole treatment.

Overdosage should be treated symptomatically with supportive measures and gastric lavage with activated charcoal as necessary. Symptoms of acute overdosage would be expected to include gastrointestinal disturbances, abdominal pain, headache, dizziness, pyrexia and convulsions.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

P02C A01 Antinematodal Agents, Benzimadazole Derivatives

Anthelmintic


Go to top of the page
5.2 Pharmacokinetic properties

Mebendazole is poorly absorbed from the gastrointestinal tract (5–10%) and undergoes extensive first pass elimination, being metabolised in the liver, eliminated in the bile as unchanged drug and metabolites and excreted in the faeces. Only about 2% of the drug is excreted unchanged or as metabolites in the urine. Mebendazole is a highly bound protein


Go to top of the page
5.3 Preclinical safety data

No data of relevance which is additional to that already included in other sections of the SPC.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Sorbitol E420

Orange Flavour

Magnesium stearate

Povidone K30

Maize Starch

Croscarmellose sodium

Sodium saccharin


Go to top of the page
6.2 Incompatibilities

None


Go to top of the page
6.3 Shelf life

3 years


Go to top of the page
6.4 Special precautions for storage

Do not store above 25°C. Store in the original package.


Go to top of the page
6.5 Nature and contents of container

250 micron white, opaque rigid, uPVC 20µ Aluminium foil blisters in cardboard cartons in packs of two, four tablets or eight tablets.


Go to top of the page
6.6 Special precautions for disposal and other handling

None given.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Thornton & Ross Limited

Linthwaite

Huddersfield

West Yorkshire

HD7 5QH

United Kingdom


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 00240/0085


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

6 September 2002


Go to top of the page
10. DATE OF REVISION OF THE TEXT

05/05/2010


Go to top of the page
11 DOSIMETRY (IF APPLICABLE)

Not Applicable


Go to top of the page
12 INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS (IF APPLICABLE)

Not Applicable



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/25471/SPC/


Active Ingredients/Generics

 
   mebendazole